no more compounding glp 1 drugs GLP-1 from the Gray Market Have patients been harmed by

Description

This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed. The Obesity Action Coalition (OAC), The Obesity Society (TOS), and The Obesity Medicine Association (OMA) have released a statement expressing their concerns for patients using the compounded GLP-1 alternatives

Currently, in vitro studies on peptide-mediated DDIs, which would provide better in vitro to in vivo extrapolation, remain poorly established

GLP-1 innovation vector (3): Manufacturing and supply chain After more than a year of severe shortages, both semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) have recently come off the FDAs shortage listan encouraging signal that supply is stabilizing